# Anavex Life Sciences
 (stock symbol: AVXL) Logo in transparent PNG format

## Anavex Life Sciences
 Logo large

### Anavex Life Sciences
 Logo large Download PNG (37.38 KB)

![Anavex Life Sciences
 Logo large Download PNG (37.38 KB)](/img/orig/AVXL_BIG-e7120798.png)

## Anavex Life Sciences
 Logo icon format

### Anavex Life Sciences
 Logo icon format Download PNG (11.72 KB)

![Anavex Life Sciences
 Logo icon format Download PNG (11.72 KB)](/img/orig/AVXL-65ad29dc.png)

## Anavex Life Sciences
 Logo large for dark backgrounds

### Anavex Life Sciences
 Logo large for dark backgrounds Download PNG (22.13 KB)

![Anavex Life Sciences
 Logo large for dark backgrounds Download PNG (22.13 KB)](/img/orig/AVXL_BIG.D-a98f81f7.png)

## Anavex Life Sciences
 Logo icon format for dark backgrounds

### Anavex Life Sciences
 Logo icon format for dark backgrounds Download PNG (5.37 KB)

![Anavex Life Sciences
 Logo icon format for dark backgrounds Download PNG (5.37 KB)](/img/orig/AVXL.D-f3a8cc92.png)

## About Anavex Life Sciences


Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.

1. Website domain: anavex.com
2. Employees: 38
3. Marketcap: $0.64 Billion USD


## Categories
- [x] ðŸ‡ºðŸ‡¸ United States
- [x] ðŸ’Š Pharmaceuticals
- [x] ðŸ§¬ Biotech
- [x] ðŸ§¬ Genomics
